A Phase 4 interventional study of loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D) and Placebo tablet in Rhinitis, Allergic, sponsored by Bayer. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-12-20.
Sponsored by Bayer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Rhinitis, Allergic with a site in Canada — 3 open to participants now, 7 under way, none of them phase 3. Rhinitis, Allergic · Canada.
Among the 49 studies in Rhinitis, Allergic with a site in Canada, this one is the 17th largest by enrollment of the 45 interventional ones that give a count, is one of 4 that started in 2018, is one of 7 in phase 4, and was the 33rd registered.
717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.
Browse Rhinitis, Allergic studies →3 of the 49 studies in Rhinitis, Allergic with a site in Canada are open now. Recruiting first, the newest first:
Dr. Anne Ellis · Sites in Canada
Ages 18–70 · Healthy volunteers
Lakehead University · Sites in Canada
Ages 19–39 · Healthy volunteers
University of British Columbia · Sites in Canada
Ages 19–40 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 17 · Phase 3 6 · Phase 4 7
First in 2003; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 82 is above the median of 68 across 552 interventional studies indexed under Rhinitis, Allergic.
Median enrollment 60 across the 45 interventional studies, 58 across the 4 observational. Of the 40 that completed or were terminated, 19 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 49 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 6 studies filed under Rhinitis, Allergic — fewer than ten, so there is no comparison to draw.
2 of the studies in Rhinitis, Allergic with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06189742Dr. Anne EllisTezepelumab in Allergic Rhinitis and Asthma Study (TEZARS) | 2026-12 |
| NCT06749093University of British ColumbiaHealth Effects of Wood Smoke and Traffic-Related Air Pollution Exposures: a Necessary Comparison | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 49 studies in Rhinitis, Allergic with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate changes in nasal airflow caused by loratadine 5 mg/pseudoephedrine sulfate 120 mg (Claritin D) tablet and fluticasone propionate 50 mcg per spray nasal spray (Flonase) in subjects suffering from nasal congestion and other allergy symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.
Drug: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D) · Drug: Placebo tablet · Drug: Fluticasone Propionate · Drug: Placebo spray
Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of each of the 4 treatments.
Drug: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D) · Drug: Placebo tablet · Drug: Fluticasone Propionate · Drug: Placebo spray
Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.
Drug: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D) · Drug: Placebo tablet · Drug: Fluticasone Propionate · Drug: Placebo spray
Treatment phase will consist of four treatment visits separated by 14 (+/- 1) days between visits. Each treatment sequence consists of a single dose of treatment each of the 4 treatments.
Drug: loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D) · Drug: Placebo tablet · Drug: Fluticasone Propionate · Drug: Placebo spray
Drug pages: Loratadine · (+)-pseudoephedrine sulfate
Single dose of Loratadine/pseudoephedrine in tablet 5 mg/120 mg orally
Placebo tablet orally
Fluticasone Propionate Nasal Spray 50mcg per spray, 2 sprays per nostril
Placebo Nasal Spray, 2 sprays per nostril
Average percent change in PNIF (Peak Nasal Inspiratory Flow) from 0 to 4 hours after dosing
Time frame: Up to 4 hours
Ran from Feb 2018 to primary completion in May 2018, 2 months.
Of 34 phase 4 interventional studies under Rhinitis, Allergic, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 38. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Loratadine · (+)-pseudoephedrine sulfate · Fluticasone